ArticleCancer medicine2026
Safety and Tolerability of Different Total Neoadjuvant Therapies in Patients With Locally Advanced Rectal Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTotal neoadjuvant therapy (TNT) is the standard treatment for locally advanced rectal cancer (LARC). Few studies have focused on the toxicity of TNT. Moreover, the differences in safety and tolerability between radiotherapy-first and chemotherapy-first strategies remain unclear. This study aimed to evaluate the differences in treatment-related toxicities between radiotherapy-first and chemotherapy-first strategies for TNT in patients with LARC.
methodsPatients with LARC who were treated with TNT at a single cancer center between June 2020 and July 2023 were retrospectively included. TNT consisted of induction chemotherapy followed by long-course chemoradiotherapy (INCT-LC-CRT) or long-course chemoradiotherapy/short-course radiotherapy followed by consolidation chemotherapy (LC-CRT-CNCT/SC-RT-CNCT). Adverse events (AEs) and treatment exposure were compared between the groups.
resultsOverall, 93 patients were included. Patients in the INCT-LC-CRT and LC-CRT-CNCT/SC-RT-CNCT groups were 28 (30.1%) and 45 (48.4%) / 20 (21.5%), respectively. Chemotherapy-related grade 3 or 4 AEs were significantly more frequent in the LC-CRT-CNCT/SC-RT-CNCT group than in the INCT-LC-CRT group (50.8% vs. 17.9%, p < 0.01) but were not significantly different between the LC-CRT-CNCT and SC-RT-CNCT groups (53.3% vs. 40.0%, p = 0.42). The proportion of patients who received a full dose of chemotherapy was higher in the INCT-LC-CRT group than in the LC-CRT-CNCT/SC-RT-CNCT group (53.6% vs. 24.6%; p < 0.01). One (3.6%) and six (9.2%) patients discontinued chemotherapy owing to AEs in the INCT-LC-CRT and LC-CRT-CNCT/SC-RT-CNCT groups, respectively.
conclusionsGrade 3 or 4 AEs during chemotherapy were more frequent and required dose modification in the LC-CRT-CNCT/SC-RT-CNCT group than in the INCT-LC-CRT group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.